Literature DB >> 9197296

Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans.

J C Eisenach1, D D Hood, R Curry, C Tong.   

Abstract

BACKGROUND: Intradermal injection of capsaicin produces brief pain followed by hyperalgesia and allodynia in humans, and the latter effects are mediated by spinal N-methyl-D-aspartate mechanisms. Amitriptyline recently was shown to antagonize N-methyl-D-aspartate receptors, and in this study, the authors sought to determine the effect of amitriptyline alone and with the opioid alfentanil on hyperalgesia and allodynia produced by intradermal injection of capsaicin.
METHODS: Forty-six healthy volunteers in the general clinical research center received repeated intradermal injections of capsaicin (100 microg) alone or before and after systemic injection of 4 mg midazolam, 25 mg amitriptyline, alfentanil by computer-controlled infusion, or amitriptyline plus alfentanil. Acute pain and areas of mechanical hyperalgesia and allodynia were determined at specified intervals. Blood was obtained for alfentanil and amitriptyline assay.
RESULTS: Capsaicin injection produced acute pain followed by hyperalgesia and allodynia. Alfentanil reduced these pain responses in a plasma-concentration-dependent manner, and reduction in hyperalgesia and allodynia correlated with reduction in acute pain. Amitriptyline alone had no effect and did not potentiate alfentanil. Alfentanil produced concentration-dependent nausea, an effect diminished by amitriptyline. DISCUSSION: These data correspond with previous studies in volunteers demonstrating reduction in hyperalgesia and allodynia after intradermal injection of capsaicin by systemically administered opioids, and they suggest that this reduction may be secondary to reduced nociceptive input by acute analgesia. These data do not support the use of acute systemic administration of amitriptyline for acute pain, hyperalgesia, and allodynia, although the roles of chronic treatment and spinal administration are being investigated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197296     DOI: 10.1097/00000542-199706000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  19 in total

1.  Effect of transdermal opioids in experimentally induced superficial, deep and hyperalgesic pain.

Authors:  T Andresen; C Staahl; A Oksche; H Mansikka; L Arendt-Nielsen; A M Drewes
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  Slow injection of nefopam reduces pain intensity associated with intravenous injection: a prospective randomized trial.

Authors:  Young Min Kim; Byung Gun Lim; Heezoo Kim; Myoung Hoon Kong; Mi Kyoung Lee; Il Ok Lee
Journal:  J Anesth       Date:  2013-11-08       Impact factor: 2.078

3.  BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Authors:  Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2019-03-01       Impact factor: 9.166

4.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

Review 5.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

6.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

7.  Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates.

Authors:  Huiping Ding; Norikazu Kiguchi; David A Perrey; Thuy Nguyen; Paul W Czoty; Fang-Chi Hsu; Yanan Zhang; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2020-08-17       Impact factor: 9.166

Review 8.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

9.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

Review 10.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.